Mark J. Mulligan, MD, is the director of the Division of Infectious Diseases & Immunology in the Department of Medicine, and director of the NYU Langone Vaccine Center. He joined NYU Langone Health in 2018. He is a translational physician-scientist who leads a research clinic and a research laboratory. He conducts vaccine clinical trials and clinical studies of emerging infections. He has studied HIV, Zika, Ebola, bird flu, 2009 pandemic influenza, and other infections with public health impact. He is now studying the novel coronavirus.
He is a graduate of the University of Notre Dame (cum laude, 1980), University of Texas Southwestern Medical School, Dallas (1984). During infectious diseases training (UAB, 1987-90) he did post-doctoral molecular virology training with Dr. Richard Compans, a renowned virologist.
Dr. Mulligan served as lead investigator for an NIH-funded HIV/AIDS Clinical Trials Unit, conducting AIDS and TB research in Atlanta, Kenya, the Philippines, and Thailand (2006-2018). He also served as the principal investigator for an NIH-funded Vaccine and Treatment Evaluation Unit (VTEU), 2007-18. This was one of nine national units funded by NIH to conduct clinical research on medical countermeasures (such as vaccines, treatments, diagnostics, biomarkers) to combat infectious disease threats to human health.
